Multiple factors impact the treatment of acute bacterial skin and skin structure infections (ABSSSI). BAXDELA is your new path forward.
aBAXDELA clinical trials included a distribution of patients with obesity, hypertension, diabetes, and renal impairment (eGFR > 15 mL/min/1.73 m2).
Diabetes, age, obesity—multiple factors impact ABSSSI treatment.See Baxdela Results
Dedicated safety studies and low rate of adverse events.See Baxdela Outcomes
Straightfoward dosing in IV, oral, or IV to oral.See Baxdela Options
Microbiological activity against susceptible gram-negative and gram-positive pathogens, and MRSA.See Response Rates
For hospital or home, streamline access with MelintAssist.Explore Baxdela Options
We apply Nobel Prize-winning science to develop new therapeutics against drug-resistant pathogens.Learn More
Melinta Therapeutics, Inc. - The Antibiotics Company
For additional information about BAXDELA, call Melinta Therapeutics at 1-844-MELINTA (1-844-635-4682) or contact the US Food and Drug Administration at 1-888-INFO-FDA (1-888-463-6332).